Cargando…

Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes

Sodium-glucose cotransporter 2 (SGLT2) inhibitor clinical studies in type 1 diabetes mellitus (T1DM) have demonstrated reduced HbA1c and lower glucose variability with increased time in optimal glucose range as well as additional benefits of reductions in weight and insulin dose without increasing t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Evans, Marc, Hicks, Debbie, Patel, Dipesh, Patel, Vinod, McEwan, Phil, Dashora, Umesh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6965597/ https://www.ncbi.nlm.nih.gov/pubmed/31813092 http://dx.doi.org/10.1007/s13300-019-00728-6

Ejemplares similares

SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes
por: Wheeler, David C., et al.
Publicado: (2020)

Defining the Role of SGLT2 Inhibitors in Primary Care: Time to Think Differently
por: Evans, Marc, et al.
Publicado: (2022)

SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice
por: Wilding, John, et al.
Publicado: (2018)

SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice
por: Ali, Amar, et al.
Publicado: (2019)

Correction to: SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice
por: Ali, Amar, et al.
Publicado: (2019)

Risk Prediction of the Diabetes Missing Million: Identifying Individuals at High Risk of Diabetes and Related Complications
por: Evans, Marc, et al.
Publicado: (2020)

Evaluation of Insulin Use and Value for Money in Type 2 Diabetes in the United Kingdom
por: Gordon, Jason, et al.
Publicado: (2013)

A Retrospective, Case-Note Survey of Type 2 Diabetes Patients Prescribed Incretin-Based Therapies in Clinical Practice
por: Evans, Marc, et al.
Publicado: (2012)

Benefits of SGLT2 inhibitors in arrhythmias
por: Gao, Jinghan, et al.
Publicado: (2022)

Treatment choice, medication adherence and glycemic efficacy in people with type 2 diabetes: a UK clinical practice database study
por: Gordon, Jason, et al.
Publicado: (2018)

Managing glycaemia in older people with type 2 diabetes: A retrospective, primary care‐based cohort study, with economic assessment of patient outcomes
por: Gordon, Jason, et al.
Publicado: (2017)

SGLT inhibitor adjunct therapy in type 1 diabetes
por: McCrimmon, Rory J., et al.
Publicado: (2018)

DELIVER: Extending the benefits of SGLT-2 inhibitors
por: Samaan, Kerollos, et al.
Publicado: (2023)

Current Utilization Trends of SGLT-2 Inhibitors in Type 2 Diabetics With Heart Failure
por: Dhillon, Puneet, et al.
Publicado: (2021)

Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes
por: Sands, Arthur T., et al.
Publicado: (2015)

Living with Type 2 Diabetes: Patient Commentary in Response to the Paper ‘SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice’
por: Evans, Marc
Publicado: (2018)

Meeting the Challenge of Virtual Diabetes Care: A Consensus Viewpoint on the Positioning and Value of Oral Semaglutide in Routine Clinical Practice
por: Evans, Marc, et al.
Publicado: (2022)

Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors: Benefits in Diabetics With Cardiovascular Disease
por: Aftab, Saba, et al.
Publicado: (2020)

What Next After Metformin in Type 2 Diabetes? Selecting the Right Drug for the Right Patient
por: Strain, W. David, et al.
Publicado: (2020)

Assessment of Unmet Clinical Need in Type 2 Diabetic Patients on Conventional Therapy in the UK
por: Bennett, Hayley, et al.
Publicado: (2014)

Retrospective Database Analysis Evaluating the Clinical Outcomes of Changing Treatment of People with Type 2 Diabetes Mellitus (T2DM) from Other DPP-4 Inhibitor Therapy to Alogliptin in a Primary Care Setting
por: Strain, W. David, et al.
Publicado: (2019)

SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?
por: Saisho, Yoshifumi
Publicado: (2020)

SGLT2 inhibitors and renal complications in type 1 diabetes
por: Petrie, John R
Publicado: (2020)

Benefits of SGLT2 Inhibitor: Preventing Heart Failure and Beyond
por: Kim, Yong Sook, et al.
Publicado: (2019)

Cardiovascular Benefit of Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors in Type 2 Diabetes: A Systematic Review
por: Georgiou, Petros, et al.
Publicado: (2021)

Metabolic and cardiovascular benefits with combination therapy of SGLT-2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

The Cost-Effectiveness of Alogliptin Versus Sulfonylurea as Add-on Therapy to Metformin in Patients with Uncontrolled Type 2 Diabetes Mellitus
por: Gordon, Jason, et al.
Publicado: (2016)

Multi-omics insights into potential mechanism of SGLT2 inhibitors cardiovascular benefit in diabetic cardiomyopathy
por: Xi, Yangbo, et al.
Publicado: (2022)

Update on developments with SGLT2 inhibitors in the management of type 2 diabetes
por: Nauck, Michael A
Publicado: (2014)

Practical Approach to Initiating SGLT2 Inhibitors in Type 2 Diabetes
por: Gomez-Peralta, Fernando, et al.
Publicado: (2017)

SGLT inhibitors in type 1 diabetes: weighing efficacy and side effects
por: Janssens, Birgit, et al.
Publicado: (2020)

Use of SGLT-2 Inhibitors in Patients With Type 1 Diabetes Mellitus
por: El Hage, Lea, et al.
Publicado: (2020)

Cardiovascular and Renal Benefits of SGLT2 Inhibitors: A Narrative Review
por: Rabizadeh, Soghra, et al.
Publicado: (2019)

The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review
por: Wilding, John P. H., et al.
Publicado: (2022)

The Health Economic Value of Changes in Glycaemic Control, Weight and Rates of Hypoglycaemia in Type 1 Diabetes Mellitus
por: McEwan, Phil, et al.
Publicado: (2016)

Factors Predictive of Weight Gain and Implications for Modeling in Type 2 Diabetes Patients Initiating Metformin and Sulfonylurea Combination Therapy
por: Gordon, Jason P., et al.
Publicado: (2015)

PSUN263 Diagnosis of Latent Autoimmune Diabetes of Adulthood Unveiled After Initiation of an SGLT2 Inhibitor
por: Patel, Goonja, et al.
Publicado: (2022)

SGLT-2 inhibitors and their potential in the treatment of diabetes
por: Rosenwasser, Rebecca F, et al.
Publicado: (2013)

Euglycemic Diabetic Ketoacidosis With SGLT-2 Inhibitor
por: Manas, F N U, et al.
Publicado: (2021)

A Narrative Review of Chronic Kidney Disease in Clinical Practice: Current Challenges and Future Perspectives
por: Evans, Marc, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fbfidkusltr3cl9f2hun8rp66a